Education
About Us
Working with TipRanks
Follow Us
Adicet Bio (GB:0HX7)
LSE:0HX7
0HX7 Stock Chart & Stats
$6.91
-$0.08(-7.54%)
At close: 4:00 PM EST
$6.91
-$0.08(-7.54%)
Day’s Range― - ―
52-Week Range$6.50 - $22.40
Previous CloseN/A
Volume2.90K
Average Volume (3M)25.58K
Market Cap
$66.41M
Enterprise Value$42.25M
Total Cash (Recent Filing)$158.53M
Total Debt (Recent Filing)$14.74M
Price to Earnings (P/E)―
Beta2.05
Next Earnings
May 12, 2026EPS Estimate
-11.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.94
Shares Outstanding9,596,407
10 Day Avg. Volume22,377
30 Day Avg. Volume25,580
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.36
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market Cap0.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-28.68
Enterprise Value/Ebitda-0.37
Forecast
1Y Price Target
$42.60Price Target Upside516.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-33.73
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyEarly clinical data in lupus nephritis and systemic lupus erythematosus showed strong renal responses, including ongoing complete renal remissions, which could boost investor confidence if durable benefits continue.
Manufacturing And Safety DifferentiationADI-001's off-the-shelf, allogeneic manufacturing approach combined with a benign safety profile that may enable outpatient dosing offers a competitive and practical advantage over autologous peers.
Regulatory Pathway And Trial DesignPlans to request an FDA meeting and initiate a pivotal lupus nephritis trial create a clearer path for defining the target indication and pivotal trial design that could support registrational progress.
Bears Say
Equity DilutionA recent large share issuance produced meaningful dilution that required reassessment of company valuation and reduces per-share upside for investors.
Execution And Regulatory RiskProgress depends on successful clinical results and regulatory alignment, introducing execution risk that could pressure the stock if key outcomes or agreements are unfavorable.
Listing And Capital-structure ConcernsA reverse stock split was implemented to maintain the exchange listing, signaling listing pressure and raising concerns about capital structure stability.
Adicet Bio News
0HX7 FAQ
What was Adicet Bio’s price range in the past 12 months?
Adicet Bio lowest share price was $6.50 and its highest was $22.40 in the past 12 months.
What is Adicet Bio’s market cap?
Adicet Bio’s market cap is $66.41M.
When is Adicet Bio’s upcoming earnings report date?
Adicet Bio’s upcoming earnings report date is May 12, 2026 which is in 51 days.
How were Adicet Bio’s earnings last quarter?
Adicet Bio released its earnings results on Mar 12, 2026. The company reported -$2.94 earnings per share for the quarter, missing the consensus estimate of -$2.91 by -$0.03.
Is Adicet Bio overvalued?
According to Wall Street analysts Adicet Bio’s price is currently Undervalued.
Does Adicet Bio pay dividends?
Adicet Bio pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Adicet Bio dividends here
What is Adicet Bio’s EPS estimate?
Adicet Bio’s EPS estimate is -11.02.
How many shares outstanding does Adicet Bio have?
Adicet Bio has 9,596,407 shares outstanding.
What happened to Adicet Bio’s price movement after its last earnings report?
Adicet Bio reported an EPS of -$2.94 in its last earnings report, missing expectations of -$2.91. Following the earnings report the stock price went up 5.849%.
Which hedge fund is a major shareholder of Adicet Bio?
Currently, no hedge funds are holding shares in GB:0HX7
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adicet Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.60 (516.50% Upside)
$42.60 (516.50% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-32.00%
12-Months-Change
Fundamentals
Return on Equity
-77.90%
Trailing 12-Months
Asset Growth
-42.89%
Trailing 12-Months
Company Description
Adicet Bio
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
0HX7 Stock 12 Month Forecast
Average Price Target
$42.60
▲(516.50% Upside)
Technical Analysis
Sutro Biopharma
―
PMV Pharmaceuticals
―
Gain Therapeutics
―
Immix Biopharma
―
Artiva Biotherapeutics, Inc.
―